NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Tasca Therapeutics

Tasca Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.tascatx.com/

Last Round

Series A

Sep 16, 2025

Total Funding Raised

$144M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Tasca Therapeutics is a biotechnology company that develops small molecule drugs for hard-to-treat oncology indications using a proprietary drug discovery platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyoncologysmall-molecule inhibitordrug discoverycancer therapeuticsprecision medicinetargeted therapyproteomicspharma licensingundruggable targetsclinical trialslipid-binding pocketsauto-palmitoylated proteinsbiotech startupdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tasca Therapeutics Comparables

Compare Tasca Therapeutics with similar companies based on industry and business-model similarity.

Tasca Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Palm Therapeutics, Inc.
84%
BridGene Biosciences
82%
Antares Therapeutics
81%

Tasca Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 16, 2025
Series ADec 10, 2024

Tasca Therapeutics Investors

Notable investors and investment history

Tasca Therapeutics investors
InvestorRounds
Invus OpportunitiesSeries A
8VCSeries A
Cure VenturesSeries A, Convertible Debt
InvusSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 25, 2026

    Grew 24% QoQ from 17 to 21 employees.

  • Apr 25, 2026

    Grew 25% QoQ, from 16 to 20 employees.

Tasca Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tasca Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tasca Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range22
Year Founded2022
Last FundingSep 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.